Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 12/20 | 0.48 |
| ▸ | EDNRB | P24530 | 11/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | IGF1R | P08069 | 3/20 | 0.47 |
| ▸ | FLT4 | P35916 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7318396 | 0.92 | EGFR (0.50) | EDNRAEDNRBEGFRIGF1RFLT4 | |
| SCHEMBL7318677 | 0.85 | EGFR (0.55) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7314794 | 0.85 | PPARD (0.49) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7319348 | 0.85 | EGFR (0.46) | EDNRAEDNRBEGFRIGF1RFLT4 | |
| SCHEMBL7341464 | 0.83 | EGFR (0.44) | EDNRAEDNRBEGFRIGF1RFLT4 | |
| SCHEMBL7310034 | 0.83 | EGFR (0.54) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7318188 | 0.83 | EGFR (0.57) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7314584 | 0.82 | EGFR (0.52) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7305494 | 0.82 | EGFR (0.51) | EGFRIGF1RFLT4KDRPPARG | |
| SCHEMBL7309582 | 0.82 | IDO1 (0.42) | EDNRAEDNRBEGFRIGF1RFLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | claimed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | EDNRA 4091/4885EDNRB 3961/4885EGFR 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.